Gyre Therapeutics, Inc. beat EPS estimates 50% of the time across 16 reported quarters (8 beats, 8 misses), averaging -13.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.08 | $-0.12 | -50.0% | Miss | |
| Q1 FY26 | $-0.06 | $-0.08 | -33.3% | Miss | |
| Q4 FY25 | $0.08 | $0.04 | -50.0% | Miss | |
| Q3 FY25 | $0.05 | $0.05 | +0.0% | Beat | |
| Q2 FY25 | $0.03 | $0.02 | -33.3% | Miss | |
| Q1 FY25 | $0.03 | $0.00 | -100.0% | Miss | |
| Q4 FY24 | not reported | $0.01 | not reported | not reported | |
| Q3 FY24 | not reported | $0.02 | not reported | not reported | |
| Q2 FY24 | not reported | $0.01 | not reported | not reported | |
| Q1 FY24 | not reported | $0.04 | not reported | not reported | |
| Q3 FY23 | $-0.05 | $-0.04 | +20.0% | Beat | |
| Q2 FY23 | $-0.07 | $-0.07 | +0.0% | Beat |
Back to GYRE overview · GYRE holders · GYRE KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.